Copyright
©2005 Baishideng Publishing Group Inc.
World J Gastroenterol. Jun 14, 2005; 11(22): 3346-3350
Published online Jun 14, 2005. doi: 10.3748/wjg.v11.i22.3346
Published online Jun 14, 2005. doi: 10.3748/wjg.v11.i22.3346
Table 2 Multivariate Cox regression analysis of factors associated with HBeAg loss.
| Variables | Relative risk | 95% CI | P |
| Age <30 (yr) | 1.0 | ||
| ≥30 (yr) | 1.995 | 0.236-16.898 | 0.526 |
| Gender male | 1.0 | ||
| female | 5.247 | 0.294-93.594 | 0.260 |
| ALT <200 IU/L | 1.0 | ||
| ≥200 IU/L | 13.158 | 1.153-142.857 | 0.038 |
| HBV DNA (LGE/mL) | 0.751 | 0.479-1.178 | 0.212 |
| Core promoter Wild | 1.0 | ||
| Mutant | 0.944 | 0.234-3.817 | 0.936 |
| Precore Wild | 1.0 | ||
| Mutant | 0.749 | 0.050-11.236 | 0.834 |
| Lamivudine Untreated | 1.0 | ||
| Treated | 9.826 | 0.765-126.290 | 0.079 |
- Citation: Kurihara T, Imazeki F, Yokosuka O, Fukai K, Kanda T, Kawai S, Saisho H. Effect of lamivudine in HBeAg-positive chronic hepatitis B: Discordant effect on HBeAg and HBV DNA according to pretreatment ALT level. World J Gastroenterol 2005; 11(22): 3346-3350
- URL: https://www.wjgnet.com/1007-9327/full/v11/i22/3346.htm
- DOI: https://dx.doi.org/10.3748/wjg.v11.i22.3346